Advertisement


Toni K. Choueiri, MD, on Cabozantinib vs Everolimus in Patients With Advanced Renal Cell Carcinoma

2015 European Cancer Congress

Advertisement

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses results of the phase III METEOR trial in advanced renal cell carcinoma, which evaluated the efficacy of cabozantinib compared to everolimus in patients with disease progression after VEGFR-targeted therapy (Abstract 4LBA).



Related Videos

Issues in Oncology

Clifford A. Hudis, MD, on Obesity, Inflammation, and Cancer

Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, summarizes his educational lecture on obesity, inflammation, and cancer—an important topic in oncology.

Issues in Oncology
Breast Cancer

Matteo Lambertini, MD, on Preserving Women’s Fertility Through Hormonal Therapy

Matteo Lambertini, MD, Dana-Farber Cancer Institute, discusses the use of LHRH agonists during chemotherapy to suppress ovarian function as a way to preserve fertility in breast cancer patients (Abstract 1957).

Global Cancer Care

Looking Ahead With the New ECCO President: Peter L. J. Naredi, MD, PhD

Incoming ECCO President, Peter L. J. Naredi, MD, PhD, of the University of Gothenburg, discusses his upcoming year as the new ECCO President, his vision for the organization, and his views on cancer treatment today.

Rolf A. Stahel, MD, on Results From the BELIEF Trial

Rolf A. Stahel, MD, of University Hospital, Zurich, discusses this phase II trial of erlotinib and bevacizumab in patients with advanced, EGFR-mutated non-small cell lung cancer without T790M mutation. The study was sponsored by The Spanish Lung Cancer Group and the European Thoracic Oncology Platform (Abstract 3BA).

Lung Cancer

Jean-Yves Douillard, MD, PhD, on New Perspectives in Small Cell Lung Cancer

Jean-Yves Douillard, MD, PhD, of Centre R Gauducheau, reviews new clinical trials and data on systemic and radiation treatment of small cell lung cancer.

Advertisement

Advertisement




Advertisement